PubMed Health⌕ Search

Biomedical subjects

Anthony J Culyer

Publications and source records attributed to Anthony J Culyer.

4 recordsLinked to original sources
PubMed2005

Involving stakeholders in healthcare decisions--the experience of the National Institute for Health and Clinical Excellence (NICE) in England and Wales.

Appeal to "stakeholders" and involving them in decisions and the processes through which decisions are made are becoming touch stones of "best practice," both clinical and managerial, in health care. Few organizations have sought to integrate stakeholders, especially patients and their caregivers, more completely than the National Institute for Health and Clinical Excellence (NICE) in England and Wales. This article outlines the circumstances in which NICE was created (1999) and the means through which it has created truly effective involvement of its many stakeholder groups. Key messages are that client involvement in decision-making is possible and can work well, but it demands commitment from the entire organization, specific managerial arrangements and, depending on the circumstances, it can be costly. Trust is an important ingredient of success.

Academies and Institutes↗
PubMed2002

Developing the revised NICE appraisal technical guidance to manufacturers and sponsors: opportunity or threat?

One of the principal roles of the National Institute for Clinical Excellence (NICE) is to appraise selected existing and emerging healthcare technologies and, as a result, produce guidance for the National Health Service (NHS) in England and Wales. A central part of this appraisal is the potential for manufacturers and sponsors to make a data submission. This paper describes the process of development of the second edition of technical guidance to manufacturers and sponsors for submission to NICE. The revision process took place during the period May 2000 and January 2001 and involved a number of key steps -- establishment of a guidance steering committee, review of current international guidelines of clinical and cost effectiveness, drafting of the guidance, detailed consultation with stakeholders, revision of the guidance and, finally, publication. The lessons learnt from revision of the NICE guidance for manufacturers and sponsors and some main issues for its future development are discussed.

Biotechnology↗